Ruediger Rueger

1.4k total citations · 1 hit paper
12 papers, 769 citations indexed

About

Ruediger Rueger is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruediger Rueger has authored 12 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruediger Rueger's work include Melanoma and MAPK Pathways (6 papers), Cancer-related Molecular Pathways (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Ruediger Rueger is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Cancer-related Molecular Pathways (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Ruediger Rueger collaborates with scholars based in Switzerland, United States and France. Ruediger Rueger's co-authors include Gwen Nichols, Jianguo Zhi, Florian Heil, Lyubomir T. Vassilev, Jean‐Yves Blay, Antoîne Italiano, Nicolas Penel, Steven A. Middleton, Axel Le Cesne and Meichun Ding and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Ruediger Rueger

12 papers receiving 763 citations

Hit Papers

Effect of the MDM2 antagonist RG7112 on the P53 pathway i... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    2012 455 citations Isabelle Ray‐Coquard, Jean‐Yves Blay et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruediger Rueger Switzerland 9 500 422 215 98 93 12 769
Nyam Kamsu-Kom France 10 662 1.3× 615 1.5× 117 0.5× 84 0.9× 80 0.9× 12 1.0k
Leslie Smetzer United States 12 570 1.1× 471 1.1× 142 0.7× 95 1.0× 161 1.7× 14 896
Monica Kong-Beltran United States 10 471 0.9× 219 0.5× 241 1.1× 118 1.2× 149 1.6× 11 918
Josep Lluís Parra United Kingdom 5 798 1.6× 352 0.8× 152 0.7× 128 1.3× 132 1.4× 6 1.1k
Anne Keating United States 13 638 1.3× 409 1.0× 192 0.9× 90 0.9× 115 1.2× 26 899
Haby Henary United States 14 376 0.8× 378 0.9× 199 0.9× 68 0.7× 117 1.3× 32 702
Silvia Paola Corona Italy 13 230 0.5× 391 0.9× 357 1.7× 54 0.6× 152 1.6× 43 689
Davide Torti Italy 12 418 0.8× 304 0.7× 116 0.5× 77 0.8× 137 1.5× 17 677
K. Papadopoulos United States 16 598 1.2× 540 1.3× 215 1.0× 103 1.1× 131 1.4× 56 1.1k
Ling Huw United States 6 649 1.3× 247 0.6× 169 0.8× 87 0.9× 183 2.0× 9 821

Countries citing papers authored by Ruediger Rueger

Since Specialization
Citations

This map shows the geographic impact of Ruediger Rueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruediger Rueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruediger Rueger more than expected).

Fields of papers citing papers by Ruediger Rueger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruediger Rueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruediger Rueger. The network helps show where Ruediger Rueger may publish in the future.

Co-authorship network of co-authors of Ruediger Rueger

This figure shows the co-authorship network connecting the top 25 collaborators of Ruediger Rueger. A scholar is included among the top collaborators of Ruediger Rueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruediger Rueger. Ruediger Rueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Ang, Joo Ern, Ákos Pál, Yasmin J. Asad, et al.. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics. 16(10). 2315–2323. 8 indexed citations
2.
Ducret, Axel, Sven Michel, Tomáš Raček, et al.. (2015). Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. Proceedings of the National Academy of Sciences. 112(34). 10732–10737. 41 indexed citations
3.
Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations
4.
Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations
5.
Ray‐Coquard, Isabelle, Jean‐Yves Blay, Antoîne Italiano, et al.. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The Lancet Oncology. 13(11). 1133–1140. 455 indexed citations breakdown →
6.
Nichols, Gwen, Monica Reckner, Lyubomir T. Vassilev, et al.. (2011). Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3039–3039. 6 indexed citations
7.
Ray-Coquard, I. L., Jean‐Yves Blay, Antoîne Italiano, et al.. (2011). Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study.. Journal of Clinical Oncology. 29(15_suppl). 10007b–10007b. 10 indexed citations
8.
Niu, Huifeng, Petra Goelzer, Ruediger Rueger, et al.. (2010). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression. The Journal of Clinical Pharmacology. 50(12). 1397–1405. 8 indexed citations
9.
Zhang, Wenjun, Abigail McElhinny, Shalini Singh, et al.. (2010). Automated Brightfield Dual-Color In Situ Hybridization for Detection of Mouse Double Minute 2 Gene Amplification in Sarcomas. Applied immunohistochemistry & molecular morphology. 19(1). 54–61. 15 indexed citations
10.
Soria, J.C., Udai Banerji, Ratislav Bahleda, et al.. (2010). 365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour. European Journal of Cancer Supplements. 8(7). 115–116. 1 indexed citations
11.
Berkofsky‐Fessler, Windy, Paul Delmar, Juliette Molnos, et al.. (2009). Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Molecular Cancer Therapeutics. 8(9). 2517–2525. 18 indexed citations
12.
Niu, Huifeng, Ruediger Rueger, Jonathan Deutsch, et al.. (2009). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. Clinical Cancer Research. 15(23). 7368–7374. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nyam Kamsu-Kom Breakdown of academic impact, for papers by Leslie Smetzer Breakdown of academic impact, for papers by Monica Kong-Beltran Breakdown of academic impact, for papers by Josep Lluís Parra Breakdown of academic impact, for papers by Anne Keating Breakdown of academic impact, for papers by Haby Henary Breakdown of academic impact, for papers by Silvia Paola Corona Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by K. Papadopoulos Breakdown of academic impact, for papers by Ling Huw
Rankless by CCL
2026